Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. Eastern Time. This virtual event, occurring from February 14-16, 2023, will showcase the company's progress in developing therapeutics for rare endocrine diseases and related tumors. Notably, Crinetics is advancing Paltusotine, an investigational SST2 agonist, through Phase 3 trials for acromegaly and Phase 2 for carcinoid syndrome. The live broadcast and archived version will be available on the Events & Presentations page of Crinetics’ website.

SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023.

Details of the presentation are as follows:

Date: Tuesday, February 14, 2023
Time: 3:40 p.m. Eastern Time

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist in development for congenital hyperinsulinism, and for CRN04894, an investigational, oral ACTH antagonist in development for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Contacts:
Chas Schultz
VP, IR & Corporate Communications
cschultz@crinetics.com
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

FAQ

When is Crinetics Pharmaceuticals participating in the SVB Securities Global Biopharma Conference?

Crinetics Pharmaceuticals will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. Eastern Time.

What is the focus of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.

What are the main drug candidates under development by Crinetics Pharmaceuticals?

The main drug candidates include Paltusotine for acromegaly and carcinoid syndrome, CRN04777 for congenital hyperinsulinism, and CRN04894 for Cushing’s disease and congenital adrenal hyperplasia.

How can I access the live and archived webcast of Crinetics Pharmaceuticals' presentation?

The live and archived webcast can be accessed on the Events & Presentations page in the Investors section of Crinetics’ website.

What is the significance of Paltusotine in Crinetics Pharmaceuticals' pipeline?

Paltusotine is significant as it is in Phase 3 clinical development for treating acromegaly and is a key product in Crinetics' pipeline.